SPR206

DRUG3 trials

Sponsors

Spero Therapeutics

Conditions

Healthy VolunteersRenal Impairment

Phase 1

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers

CompletedNCT03792308

Spero TherapeuticsHealthy Volunteers

Start: 2018-12-18End: 2019-12-23Updated: 2020-01-10

Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function

CompletedNCT04865393

Spero TherapeuticsRenal Impairment

Start: 2021-06-08End: 2021-12-06Updated: 2024-04-15

Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers

CompletedNCT04868292

Spero TherapeuticsHealthy Volunteers

Start: 2021-06-03End: 2021-09-29Updated: 2021-11-17

Related Papers

Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206.

2021-08-0234 citations